-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M

Benzinga·10/22/2026 05:27:58
Listen to the news
  • Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025
  • Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025
  • Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million
  • Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT